falsefalse

ASH 2024: Updates in the Treatment of CLL - Episode 5

Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL

Panelists discuss how the AMPLIFY trial evaluated acalabrutinib-venetoclax-obinutuzumab (AVO) vs acalabrutinib-venetoclax (AV) as frontline therapy options, highlighting the impressive depth of response with both regimens while noting the additional toxicity profile associated with the triplet combination.

Video Player is loading.
Current Time 0:00
Duration 2:42
Loaded: 0%
Stream Type LIVE
Remaining Time 2:42
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Video content above is prompted by the following:

  • One other frontline doublet or triplet therapy was from the AMPLIFY trial looking AVO or AV. Can you share some key highlights and your impressions so far?
x